1. Scrip
  2. >>Business

UK's Cambridge Keen To Challenge US Counterpart With Biotech Start-Ups

CIC Raises £225m For Second Fund

 
• By Kevin Grogan

Cambridge Innovation Capital partner Robert Tansley tells Scrip that the UK has "a really strong history of innovation in biological sciences and Cambridge has been at the forefront” but this has not equated to a substantial number of biotech companies “where we have lagged significantly behind the US."

Cambridge
Hotbed Of Innovation; University of Cambridge • Source: Shutterstock

The dominance of the Cambridge-Boston cluster in the global biotech world shows no signs of diminishing but plans are afoot in the original Cambridge to boost the number of UK spin-out companies that can turn strong scientific ideas into viable concerns.

Leading the charge is Cambridge Innovation Capital (CIC), the venture capital investor focused on building deeptech and life sciences businesses...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

EY Recommends Focusing On Fundamentals, Waiting For Prime Deal Conditions

 
• By Joseph Haas

Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.